Literature DB >> 23293579

Mutational spectrum of smith-lemli-opitz syndrome patients in hungary.

I Balogh1, K Koczok, G P Szabó, O Török, K Hadzsiev, G Csábi, L Balogh, E Dzsudzsák, E Ajzner, L Szabó, V Csákváry, A V Oláh.   

Abstract

Smith-Lemli-Opitz (SLO) syndrome is an autosomal recessive disorder characterized by multiple congenital abnormalities and mental retardation. The condition is caused by the deficiency of 7-dehydrocholesterol reductase (DHCR7) which catalyzes the final step in cholesterol biosynthesis. Biochemical diagnosis is based on increased concentration of 7-dehydrocholesterol (7-DHC) in the patient serum. Both life expectancy and quality of life are severely affected by the disease. The estimated prevalence of SLO syndrome ranges between 1:20,000 and 1:40,000 among Caucasians. Although the mutational spectrum of the disease is wide, approximately 10 mutations are responsible for more than 80% of the cases. These mutations show a large interethnic variability. There are no mutation distribution data from Hungary to date. Thirteen patients were diagnosed with SLO syndrome in our laboratory. As first-line tests, serum 7-DHC and total cholesterol were measured and, in positive cases, molecular genetic analysis of the DHCR7 gene was performed. Complete genetic background of the disease could be identified in 12 cases. In 1 case only 1 mutation was detected in a heterozygote form. One patient was homozygous for the common splice site mutation c.964-1G>C, while all other patients were compound heterozygotes. One novel missense mutation, c.374A>G (p.Tyr125Cys) was identified.

Entities:  

Keywords:  7-Dehydrocholesterol; Cholesterol; DHCR7; Hungary; Mutation; SLO syndrome

Year:  2012        PMID: 23293579      PMCID: PMC3531926          DOI: 10.1159/000343923

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  34 in total

Review 1.  Malformation syndromes due to inborn errors of cholesterol synthesis.

Authors:  Forbes D Porter
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

2.  A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES.

Authors:  D W SMITH; L LEMLI; J M OPITZ
Journal:  J Pediatr       Date:  1964-02       Impact factor: 4.406

3.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

4.  Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis.

Authors:  Gergely Ivady; Laszlo Madar; Bela Nagy; Ferenc Gonczi; Eva Ajzner; Erika Dzsudzsak; Lenka Dvořáková; Eva Gombos; Janos Kappelmayer; Milan Macek; Istvan Balogh
Journal:  J Cyst Fibros       Date:  2011-02-04       Impact factor: 5.482

5.  Mutations in the human DHCR7 gene.

Authors:  M Witsch-Baumgartner; J Löffler; G Utermann
Journal:  Hum Mutat       Date:  2001-03       Impact factor: 4.878

6.  Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome.

Authors:  Zeljka Korade; Libin Xu; Richard Shelton; Ned A Porter
Journal:  J Lipid Res       Date:  2010-08-11       Impact factor: 5.922

7.  Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay.

Authors:  Hans C Andersson; Lisa Kratz; Richard Kelley
Journal:  Am J Med Genet       Date:  2002-12-15

8.  Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations.

Authors:  M Witsch-Baumgartner; E Ciara; J Löffler; H J Menzel; U Seedorf; J Burn; G Gillessen-Kaesbach; G F Hoffmann; B U Fitzky; H Mundy; P Clayton; R I Kelley; M Krajewska-Walasek; G Utermann
Journal:  Eur J Hum Genet       Date:  2001-01       Impact factor: 4.246

Review 9.  Determinants of vitamin D status: focus on genetic variations.

Authors:  Diane Berry; Elina Hyppönen
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-07       Impact factor: 2.894

10.  Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Authors:  Thomas J Wang; Feng Zhang; J Brent Richards; Bryan Kestenbaum; Joyce B van Meurs; Diane Berry; Douglas P Kiel; Elizabeth A Streeten; Claes Ohlsson; Daniel L Koller; Leena Peltonen; Jason D Cooper; Paul F O'Reilly; Denise K Houston; Nicole L Glazer; Liesbeth Vandenput; Munro Peacock; Julia Shi; Fernando Rivadeneira; Mark I McCarthy; Pouta Anneli; Ian H de Boer; Massimo Mangino; Bernet Kato; Deborah J Smyth; Sarah L Booth; Paul F Jacques; Greg L Burke; Mark Goodarzi; Ching-Lung Cheung; Myles Wolf; Kenneth Rice; David Goltzman; Nick Hidiroglou; Martin Ladouceur; Nicholas J Wareham; Lynne J Hocking; Deborah Hart; Nigel K Arden; Cyrus Cooper; Suneil Malik; William D Fraser; Anna-Liisa Hartikainen; Guangju Zhai; Helen M Macdonald; Nita G Forouhi; Ruth J F Loos; David M Reid; Alan Hakim; Elaine Dennison; Yongmei Liu; Chris Power; Helen E Stevens; Laitinen Jaana; Ramachandran S Vasan; Nicole Soranzo; Jörg Bojunga; Bruce M Psaty; Mattias Lorentzon; Tatiana Foroud; Tamara B Harris; Albert Hofman; John-Olov Jansson; Jane A Cauley; Andre G Uitterlinden; Quince Gibson; Marjo-Riitta Järvelin; David Karasik; David S Siscovick; Michael J Econs; Stephen B Kritchevsky; Jose C Florez; John A Todd; Josee Dupuis; Elina Hyppönen; Timothy D Spector
Journal:  Lancet       Date:  2010-06-10       Impact factor: 79.321

View more
  8 in total

1.  Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets.

Authors:  J L Cross; J Iben; C L Simpson; A Thurm; S Swedo; E Tierney; J E Bailey-Wilson; L G Biesecker; F D Porter; C A Wassif
Journal:  Clin Genet       Date:  2014-06-06       Impact factor: 4.438

2.  Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.

Authors:  Anna V Oláh; Gabriella P Szabó; József Varga; Lídia Balogh; Györgyi Csábi; Violetta Csákváry; Wolfgang Erwa; István Balogh
Journal:  Eur J Pediatr       Date:  2013-01-15       Impact factor: 3.183

3.  Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol.

Authors:  Phillip A Wages; Hye-Young H Kim; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2018-08-07       Impact factor: 5.922

4.  Vulnerability of DHCR7+/- mutation carriers to aripiprazole and trazodone exposure.

Authors:  Zeljka Korade; Thiago C Genaro-Mattos; Keri A Tallman; Wei Liu; Krassimira A Garbett; Katalin Koczok; Istvan Balogh; Karoly Mirnics; Ned A Porter
Journal:  J Lipid Res       Date:  2017-09-28       Impact factor: 5.922

5.  7DHC-induced changes of Kv1.3 operation contributes to modified T cell function in Smith-Lemli-Opitz syndrome.

Authors:  András Balajthy; Sándor Somodi; Zoltán Pethő; Mária Péter; Zoltán Varga; Gabriella P Szabó; György Paragh; László Vígh; György Panyi; Péter Hajdu
Journal:  Pflugers Arch       Date:  2016-06-17       Impact factor: 3.657

6.  Sharing genetic variants with the NGS pipeline is essential for effective genomic data sharing and reproducibility in health information exchange.

Authors:  Jeong Hoon Lee; Solbi Kweon; Yu Rang Park
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

7.  Biochemical and Clinical Effects of Vitamin E Supplementation in Hungarian Smith-Lemli-Opitz Syndrome Patients.

Authors:  Katalin Koczok; László Horváth; Zeljka Korade; Zoltán András Mezei; Gabriella P Szabó; Ned A Porter; Eszter Kovács; Károly Mirnics; István Balogh
Journal:  Biomolecules       Date:  2021-08-17

8.  Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report.

Authors:  Maurizio Delvecchio; Biagio Rapone; Simonetta Simonetti; Simona Fecarotta; Graziana De Carlo; Elvira Favoino; Maria Teresa Loverro; Anna Maria Isdraele Romano; Federica Taurino; Edoardo Di Naro; Antonio Gnoni
Journal:  Ital J Pediatr       Date:  2020-10-28       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.